Antibody avidity fulfills a number of myeloma In the continued seek for revolutionary treatments to overcome refractory and relapsed most cancers, new preclinical get the job done in a number of myeloma exhibits that expanding binding avidity by targeting two antigens in a single T mobile-participating trispecific antibody boosts anti-tumor activit